Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support (CARE-ACT)

UCB

Status: Completed

Conditions: Idiopathic Parkinson's Disease

Treatments: Drug: Neupro®

Study type: Observational

Funder types: Industry

Identifiers

NCT01330290

SP0939

Details and patient eligibility

About

The study objective is to evaluate advantages and disadvantages of Neupro® versus oral anti-Parkinson medication by caregivers and physicians in idiopathic Parkinson's Disease patients requiring caregiver support in nursing home or outpatient care settings.

Enrollment: 148 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Only patients having signed the consent form regarding study information, data transfer and data use
• The patients suffer from idiopathic Parkinson's Disease (iPD) treated with a combination of L-dopa or another oral iPD drug and Neupro® for at least one month
• The patients require caregiver support documented as per medical records (e.g. based on German level of care intensity 1 or greater)
• The decision to prescribe Neupro® must have been made by the physician independent of his/her decision to include the patient in the study

Exclusion criteria

• Patients not fulfilling the inclusion criteria
• And according to Summary of Product Characteristics (SmPC): Hypersensitivity to the active substance or to any of the excipients, magnetic resonance tomography (MRT) or cardioversion

Trial design

148 participants in 1 patient group

Neupro® Treatment

Description:

Routine treatment (2, 4, 6, 8, 10, 12, 14, 16 mg/24 hours) as per approved label in European Union (EU)/in accordance with the terms of the local marketing authorization for Neupro®

Treatment:

Drug: Neupro®